Kingchem (Liaoning) Life Science Past Earnings Performance
Past criteria checks 3/6
Kingchem (Liaoning) Life Science has been growing earnings at an average annual rate of 22.6%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 8.9% per year. Kingchem (Liaoning) Life Science's return on equity is 6.8%, and it has net margins of 22.1%.
Key information
22.6%
Earnings growth rate
16.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -8.9% |
| Return on equity | 6.8% |
| Net Margin | 22.1% |
| Next Earnings Update | 27 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Kingchem (Liaoning) Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 677 | 150 | 117 | 29 |
| 31 Dec 23 | 767 | 174 | 118 | 30 |
| 30 Sep 23 | 736 | 153 | 126 | 29 |
| 30 Jun 23 | 774 | 173 | 115 | 28 |
| 31 Mar 23 | 743 | 152 | 106 | 28 |
| 01 Jan 23 | 717 | 161 | 105 | 26 |
| 30 Sep 22 | 714 | 179 | 107 | 23 |
| 30 Jun 22 | 670 | 148 | 104 | 25 |
| 31 Mar 22 | 609 | 116 | 97 | 25 |
| 31 Dec 21 | 549 | 85 | 90 | 25 |
| 31 Dec 20 | 464 | 59 | 77 | 21 |
| 31 Dec 19 | 415 | 58 | 69 | 17 |
| 31 Dec 18 | 301 | 27 | 58 | 13 |
Quality Earnings: 301509 has high quality earnings.
Growing Profit Margin: 301509's current net profit margins (22.1%) are higher than last year (20.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301509's earnings have grown significantly by 22.6% per year over the past 5 years.
Accelerating Growth: 301509's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301509 had negative earnings growth (-1.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 301509's Return on Equity (6.8%) is considered low.